Which funds bought or sold ELAN in Q3 2026?
Elanco Animal Health Inc. 3 funds bought, 5 sold, out of 109 tracked funds that have filed for Q3 2026. Among active managers, the estimated net flow was −$313M.
Holdings as of Sep 30, 2026 (Q3 2026)13F deadline Nov 16, 2026 (45 days after quarter end)
- Marshall Wace+$125M
- ExodusPoint+$60M
- GlenviewNEW+$524K
- Citadel−$185M
- T. Rowe Price−$143M
- Dodge & Cox−$134M
- Jennison−$34M
- MaverickOUT−$2M
Top 10 each side. NEW = opened a position, OUT = sold the whole position.
Bought (3)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| Marshall Wace Quant & multi-strategy | Added+126.1% | +$125M | $224M |
| ExodusPoint Quant & multi-strategy | Added+597.5% | +$60M | $70M |
| Glenview Hedge fund | New | +$524K | $524K |
Sold (5)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| Citadel Quant & multi-strategy | Trimmed-85.6% | −$185M | $31M |
| T. Rowe Price Asset manager | Trimmed-22.2% | −$143M | $501M |
| Dodge & Cox Value investor | Trimmed-8.9% | −$134M | $1.4B |
| Jennison Growth / crossover | Trimmed-34.1% | −$34M | $67M |
| Maverick Hedge fund | Sold out | −$2M | — |
Source: SEC EDGAR Form 13F-HR for each fund, holdings as of Sep 30, 2026. Shares only (options excluded). Estimated $ = change in shares × quarter-end price. Funds may have traded since. Methodology. Not investment advice.